Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
NCT04165564 · View on ClinicalTrials.gov ↗
Study Summary
DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.
Conditions Studied
Interventions
- OTHER Institutional standard of care
- OTHER Biosamples of airway and blood
Study Locations (19)
Pennsylvania
- American College of Radiology [Administrative Site] — Philadelphia
- University of Pennsylvania School of Medicine — Philadelphia
- Temple University — Philadelphia
- University of Pittsburgh Medical Center — Pittsburgh
California
- University of California Los Angeles — Los Angeles
- VA Greater LA Healthcare System — Los Angeles
- Naval Medical Center San Diego — San Diego
Alabama
- University of Alabama, Birmingham — Birmingham
Iowa
- University of Iowa — Iowa City
Maryland
- Walter Reed Army Medical Center — Bethesda
Massachusetts
- VA Boston Healthcare System — Boston
Michigan
- University of Michigan — Ann Arbor
Minnesota
- Mayo Clinic — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165564
The ClinicalTrials.gov registry entry for NCT04165564 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 150 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions — of which Institutional standard of care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04165564 reports 19 study locations spanning 14 distinct geographic areas — top geographies include Pennsylvania, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04165564 about?
NCT04165564 is a clinical study titled "DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers". DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign ind...
What is the current status of trial NCT04165564?
This trial is currently active not recruiting. The enrollment target is 85 participants. The study started on 2020-08-24. Estimated completion is 2026-12.
What conditions does trial NCT04165564 study?
This clinical trial studies the following conditions: Pulmonary Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04165564?
The interventions under investigation include: Institutional standard of care (OTHER), Biosamples of airway and blood (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04165564?
This trial is sponsored by Boston University, which has 150 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04165564 being conducted?
This trial has 19 study locations across Alabama, California, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.